Evaluation of the efficacy and safety of pregabalin, venlafaxine, and
carbamazepine in patients with painful diabetic peripheral neuropathy. A
randomized, double-blind trial.
Author(s): Razazian N(1), Baziyar M, Moradian N, Afshari D, Bostani A, Mahmoodi M.
Affiliation(s): Author information:
(1)Department of Neurology, Imam Reza Hospital, College of Medicine, Kermanshah
University of Medical Sciences, Kermanshah, Iran.
Publication date & source: 2014, Neurosciences (Riyadh). , 19(3):192-8
OBJECTIVE: To evaluate the efficacy and safety of carbamazepine, pregabalin, and
venlafaxine in patients with painful diabetic neuropathy (PDN).
METHODS: Our study was performed as a randomized, double-blind, parallel-group
clinical trial between December 2012 and December 2013 at Kermanshah University
of Medical Sciences, Kermanshah, Iran. Two hundred and fifty-seven patients with
clinically definite PDN were randomized to receive, carbamazepine, venlafaxine,
or pregabalin. The primary outcome was subjective pain as assessed by the visual
analogue scale (VAS). Secondary outcomes consisted of sleep, mood, and work
interference assessments, and a percentage of patients achieving at least 50%
reduction in pain intensity.
RESULTS: Means of VAS scores for carbamazepine, pregabalin, and venlafaxine
treatment groups at the baseline (74.5, 82.3, and 74.5) and endpoint (39.6, 33.4,
and 46.6) revealed significant reduction, although pregabalin was more
efficacious than carbamazepine, and venlafaxine. Improvements in means scores of
sleep, mood, and work interferences were identified in all treatment groups.
CONCLUSION: This study showed the efficacy of venlafaxine, pregabalin, and
carbamazepine in pain reduction in patients with diabetic neuropathy, although
pregabalin was shown to be superior to carbamazepine, and venlafaxine in
relieving pain, no significant superiority was shown between carbamazepine, and
venlafaxine.
|
